BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/23/2025 8:18:08 AM | Browse: 14 | Download: 26
 |
Received |
|
2024-10-27 13:44 |
|
Peer-Review Started |
|
2024-10-27 13:44 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-02-12 04:15 |
|
Revised |
|
2025-02-25 03:36 |
|
Second Decision |
|
2025-03-11 02:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-03-12 01:28 |
|
Articles in Press |
|
2025-03-12 01:28 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-30 07:31 |
|
Publish the Manuscript Online |
|
2025-06-23 07:18 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jiyoon Park, Amr Sayed, Syed Alishan Nasir and Joseph K Lim |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph K Lim, MD, Professor, Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, Yale Liver Center, 333 Cedar Street, LMP 1080, New Haven, New Haven, CT 06520, United States. joseph.lim@yale.edu |
| Key Words |
Hepatitis D virus; Antiviral therapy; Interferon; Bulevirtide; Tobevibart; Elebsiran; Guidelines; Clinical trials |
| Core Tip |
Current treatment of hepatitis delta virus (HDV) infection with off-label use of pegylated interferon (Peg-IFN) is limited by poor efficacy and safety. Guidelines of major international liver societies including the American Association for the Study of Liver Diseases, European Association for the Study of Liver and Asian Pacific Association for the Study of the Liver provide recommendations for contemporary management of HDV infection with Peg-IFN and/or bulevirtide. Significant unmet medical needs remain in the treatment of HDV and recent advances in drug development offer hope for significant improvement in virologic response rates and clinical outcomes. This review summarizes trial design and available efficacy data from key phase 2 and 3 trials for investigational therapies including entry inhibitors (bulevirtide), prenylation inhibitors (lonafarnib), novel interferons (peginterferon lambda), RNA interference molecules (JNJ-3989, elebsiran), monoclonal antibodies (tobevibart), and nucleic acid polymers (REP2139), and report important advances with monotherapy and combination regimens which are associated with high rates of virologic response. |
| Publish Date |
2025-06-23 07:18 |
| Citation |
<p>Park J, Sayed A, Nasir SA, Lim JK. Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs. <i>World J Virol</i> 2025; 14(2): 102673</p> |
| URL |
https://www.wjgnet.com/2220-3249/full/v14/i2/102673.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v14.i2.102673 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
